GlaxoSmithKline News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

11:16 ET

6-K: Blenrep Shows Significant Overall Survival Benefit, Reducing the Risk of Death by 42% in Multiple Myeloma at or After First Relapse

Dec 9 14:41 ET

6-K: Blenrep Combination Accepted for Priority Review in China in Relapsed/Refractory Multiple Myeloma

Dec 9 08:11 ET

6-K: Us Fda Accepts Gsk's Submission for the Use of Nucala (Mepolizumab) in Copd

Dec 9 08:01 ET

6-K: Gsk and Zhifei Revise and Extend Strategic Vaccine Collaboration in China

Dec 5 06:04 ET

6-K: Transaction Notification

Dec 2 11:20 ET

6-K: Total Voting Rights and Capital

Dec 2 11:16 ET

6-K: Gsk's Fully Liquid Menveo Meningococcal Vaccine Approved by European Commission

Nov 27 06:13 ET

6-K: Blenrep Combinations Accepted for Review by the Us Fda for the Treatment of Relapsed/Refractory Multiple Myeloma

Nov 25 07:17 ET

6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan

Nov 22 09:25 ET

6-K: Transaction Notification

Nov 19 10:56 ET

6-K: Linerixibat Shows Positive Phase Iii Results in Cholestatic Pruritus in Primary Biliary Cholangitis

Nov 19 08:11 ET

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(9.5%)

Nov 15 16:24 ET

6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma

Nov 14 06:46 ET

6-K: Block Listing Six Monthly Return

Nov 13 10:17 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(11.2%)

Nov 12 16:39 ET

6-K: Transaction Notification

Nov 12 10:33 ET

6-K: Gsk Publishes Provisional Dividend Dates

Nov 12 09:48 ET

6-K: Total voting rights and capital

Nov 1 11:22 ET

6-K: Transaction notification

Oct 30 12:32 ET